SHR-8068 + adebrelimab + platinum-based chemotherapy

This is a combination therapy consisting of three components: **SHR-8068** is a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA‑4), acting as an immune checkpoint inhibitor to enhance antitumor immune responses[1][2][3][4]. **Adebrelimab** is a humanized IgG4 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1), blocking its interaction with PD‑1 and thereby promoting T-cell-mediated antitumor activity[6][8]. The third component, **platinum-based chemotherapy**, typically includes agents such as oxaliplatin, cisplatin, or carboplatin, which are DNA-damaging chemotherapeutic drugs used in various solid tumors. This combination regimen is under clinical investigation for the treatment of advanced gastric and esophageal cancers and metastatic colorectal adenocarcinoma after failure of standard therapies[2][3][5]. The approach aims to synergistically combine immune checkpoint blockade with cytotoxic chemotherapy to improve response rates in difficult-to-treat cancers.

Brand names

None

Other names

anti-CTLA-4 monoclonal antibody SHR-8068anti-CTLA4 monoclonal antibody SHR-8068anti-CTLA 4 monoclonal antibody SHR-8068anti-PD-L1 monoclonal antibody adebrelimabanti-PD-L-1 monoclonal antibody adebrelimabanti-PD-L 1 monoclonal antibody adebrelimab